Cell-permeable succinate compounds
The present invention provides novel cell-permeable succinates and cell permeable precursors of succinateaimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Kreb's cycle. Not all Kreb's cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.
1. A compound according to Formula (IA)
or a pharmaceutically acceptable salt thereof, wherein
Z is —CH 2 —CH 2 —,
A is —SR, and R is
B is selected from the group consisting of —O—R′, —SR″′ and —OH; and R′ is selected from the group consisting of:
R″′ is selected from the group consisting of:
R 1 and R 3 are independently different or identical and are selected from the group consisting of H, Me, Et, propyl, i-propyl, butyl, iso-butyl, O-acyl, O-alkyl, N-acyl, N-alkyl, Xacyl, CH 2 Xalkyl, CH 2 X-acyl, F, CH 2 COOH, and CH 2 CO 2 alkyl,
X is selected from the group consisting of O, NR 6 , and S,
R 2 is selected from the group consisting of Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, C(O)CH 3 , C(O)CH 2 C(O)CH 3 , and C(O)CH 2 CH(OH)CH 3 ,
R 6 is selected from the group consisting of H, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, acetyl, acyl, propionyl, benzoyl, formula (II), and formula (VIII),
X 5 is selected from the group consisting of Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, —COOH, —C(═O)XR 6 ,
and CONR 1 R 3 ,
X 7 is R 1 or —NR 1 R 3 ,
R 9 is selected from the group consisting of H, Me, Et and O 2 CCH 2 CH 2 COX 6 R 8 ,
R 10 is selected from the group consisting of Oacyl, NHalkyl, NHacyl, and O 2 CCH 2 CH 2 COX 6 R 8 ,
X 6 is selected from the group consisting of 0 , NR 8 , and NR 6 R 8 , wherein R 6 and R 8 are independently different or identical and R 8 is selected from the group consisting of H, alkyl, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, acetyl, acyl, propionyl, benzoyl, formula (II), and formula (VIII),
R 11 and R 12 are independently different or identical and are selected from the group consisting of H, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, acetyl, propionyl, benzoyl, —CH 2 Xalkyl, and —CH 2 Xacyl,
R c and R d are independently different or identical and are CH 2 Xalkyl or CH 2 Xacyl, R 13 , R 14 and R 15 are independently different or identical and are selected from the group consisting of H, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, —COOH, O-acyl, O-alkyl, N-acyl, N-alkyl, Xacyl, and CH 2 Xalkyl;
Substituents on R 13 and R 14 or R 13 and R 15 may bridge to form a cyclic system, R f , R g and R h are independently different or identical and are selected from the group consisting of Xacyl, —CH 2 Xalkyl, —CH 2 X—acyl and R 9 ,
alkyl is selected from the group consisting of Me, Et, propyl, i-propyl, butyl, and iso-butyl,
acyl is selected from the group consisting of formyl, acetyl, propionyl, isopropionyl, byturyl, tert-butyryl, pentanoyl, and benzoyl,
acyl and/or alkyl may be optionally substituted, with the proviso that the compound is not
2. A compound according to Formula (IA)
or a pharmaceutically acceptable salt thereof, wherein
Z is —CH 2 CH 2 —,
A is —SR, and R is
B is selected from the group consisting of —O—R′, —SR″′ and —OH; and
R′ and R″′ are independently different or identical and are:
R 1 and R 3 are independently different or identical and are selected from the group consisting of H, Me, Et, propyl, O—Me, O—Et, and O-propyl,
X is selected from the group consisting of O, NH, and S,
R 6 is selected from the group consisting of H, Me, and Et,
X 5 is selected from the group consisting of —H, Me, Et, —COOH, —C(═O)XR 6 , and CONR 1 R 3
X 7 is R 1 or —NR 1 R 3 , and
R 13 , R 14 and R 15 are independently different or identical and are selected from the group consisting of H, Me, Et, propyl, i-propyl, butyl, iso-butyl, t-butyl, —COOH, O-acyl, O-alkyl, N-acyl, N-alkyl, Xacyl, and CH 2 Xalkyl,
Substituents on R 13 and R 14 or R 13 and R 15 may bridge to form a cyclic system,
alkyl is selected from the group consisting of Me, Et, propyl, i-propyl, butyl, and iso-butyl,
acyl is selected from the group consisting of formyl, acetyl, propionyl, isopropionyl, byturyl, tert-butyryl, pentanoyl, and benzoyl,
acyl and/or alkyl may be optionally substituted, with the proviso that the compound is not
3. A compound according to Formula (IA)
or a pharmaceutically acceptable salt thereof, wherein
Z is —CH 2 —CH 2 —,
A is —SR, and R is
B is selected from the group consisting of —O—R′, —SR″′ and —OH; and
R′ and R″′ are independently different or identical and are selected from:
R 1 and R 3 are independently different or identical and are selected from the group consisting of H, Me, Et, propyl, O-Me, O-Et, and O-propyl,
X is selected from the group consisting of O, NH, and S,
R 6 is selected from the group consisting of H, Me, and Et,
X 5 is selected from the group consisting of —H, Me, Et, —COOH, —C(═O)OR 6 , and CONR 1 R 3 ,
X 7 is R 1 or —NR 1 R 3 , and
R 13 , R 14 and R 15 are independently different or identical and are selected from the group consisting of H, Me, Et, and —COOH,
Substituents on R 13 and R 14 or R 13 and R 15 may bridge to form a cyclic system, with the proviso that the compound is not
4. The compound according to claim 1 , wherein B is OH or SR″′.
5. The compound according to claim 1 , wherein B is OH or SR″′ and, where R″′ is
6. The compound according to claim 1 , wherein B is OH.
7. The compound according to claim 1 , wherein B is OH and R is
and X is S.
8. The compound according to claim 1 , wherein R and/or R″′ is
9. The compound according to claim 1 , wherein R and/or R″′ is
and X 5 is C(═O)XR 6 such that formula (VII) is
10. The compound according to claim 1 , wherein R and/or R″′ is
and X 5 is CONR 1 R 3 such that formula (VII) is
11. A compound, wherein the compound is selected from the group consisting of:
12. A composition comprising a compound according to claim 1 and one or more pharmaceutically or cosmetically acceptable excipients.
13. A combination of a drug substance and a compound according to claim 1 .
14. A composition comprising a drug substance and a compound according to claim 1 , wherein the drug substance has a potential drug-induced side-effect selected from i) lactic acidosis, ii) side-effects related to a Complex I defect, inhibition or malfunction, and iii) side-effects related to defect, inhibition or malfunction in aerobic metabolism upstream of complex I.
15. A kit comprising
i) a first container comprising a drug substance, which has a potential drug-induced side-effect selected i) from lactic acidosis, ii) side-effects related to a Complex I defect, inhibition or malfunction, and iii) side-effects related to defect, inhibition or malfunction in aerobic metabolism upstream of complex I, and
ii) a second container comprising a compound according to claim 1 .
16. A combination of a drug substance and a compound according to claim 2 .
17. A composition comprising a drug substance and a compound according to claim 2 , wherein the drug substance has a potential drug-induced side-effect selected from i) lactic acidosis, ii) side-effects related to a Complex I defect, inhibition or malfunction, and iii) side-effects related to defect, inhibition or malfunction in aerobic metabolism upstream of complex I.
18. A kit comprising
i) a first container comprising a drug substance, which has a potential drug-induced side-effect selected i) from lactic acidosis, ii) side-effects related to a Complex I defect, inhibition or malfunction, and iii) side-effects related to defect, inhibition or malfunction in aerobic metabolism upstream of complex I, and
ii) a second container comprising a compound according to claim 2 .
19. A combination of a drug substance and a compound according to claim 3 .
20. A composition comprising a drug substance and a compound according to claim 3 , wherein the drug substance has a potential drug-induced side-effect selected from i) lactic acidosis, ii) side-effects related to a Complex I defect, inhibition or malfunction, and iii) side-effects related to defect, inhibition or malfunction in aerobic metabolism upstream of complex I.
21. A kit comprising
i) a first container comprising a drug substance, which has a potential drug-induced side-effect selected i) from lactic acidosis, ii) side-effects related to a Complex I defect, inhibition or malfunction, and iii) side-effects related to defect, inhibition or malfunction in aerobic metabolism upstream of complex I, and
ii) a second container comprising a compound according to claim 3 .